News | Latest Breaking News Stories & Headlines

Cathal Friel co-founded Open Orphan, now know as hVivo, in 2017

hVivo's chairman Cathal Friel not seeking re-election

Irish research and clinical trial specialist hVivo said today that its chairman Cathal Friel does not intend to seek re-election to its board at its AGM later this year.

Business • 10 Apr

Shares in EGT rise 12.5% on London's AIM following IPO

Shares in European Green Transition (EGT), a company developing a range of assets aimed at capitalising on the opportunity of the green transition and which is chaired by Cathal Friel, began trading on London's AIM today.

Business • 09 Apr 24

Cathal Friel chaired EGT raises £6.4m on London's AIM

European Green Transition (EGT), a company developing a range of assets aimed at capitalising on the opportunity of the green transition and which is chaired by Cathal Friel, has conditionally raised £6.45 on London's AIM.

Business • 28 Mar 24

Cathal Friel chaired EGT to float on AIM in London

European Green Transition (EGT), a company developing a range of assets aimed at capitalising on the opportunity of the green transition and which is chaired by Cathal Friel, is to list on the Alternative Investment Market (AIM) in London.

Business • 18 Mar 24

Open Orphan's executive chairman Cathal Friel

Open Orphan opens two new testing facilities

Specialist pharmaceutical services clinical research company Open Orphan is opening a new primary FluCamp volunteer recruitment screening facility in London and a secondary FluCamp recruitment facility in Manchester.

Business • 08 Mar 22

Open Orphan names its new chief executive

Open Orphan names Khan as new CEO

Specialist pharmaceutical services clinical research company Open Orphan has appointed Yamin 'Mo' Khan as its chief executive with immediate effect.

Business • 24 Feb 22

Cathal Friel, executive chairman of Open Orphan

Open Orphan says outlook 'has never been stronger'

Dublin-listed pharmaceutical company Open Orphan has reported an operating loss of £5m for the six months to the end of June but said its business outlook has never been stronger.

Business • 30 Sep 20

Open Orphan wins new £4.3m challenge study deal

Dublin-listed pharmaceutical company Open Orphan has announced a new £4.3m contract to conduct a human viral challenge study using one of its eight traditional challenge study models for another of the global top 10 vaccine companies.

Business • 28 Sep 20

Cathal Friel, executive chairman at Open Orphan

Open Orphan agrees contract for Covid-19 vaccine trial

Dublin-listed pharmaceutical company Open Orphan has announced a new contract with Codagenix to conduct a first human trial evaluating safety and immunogenicity of a single-dose Covid-19 vaccine.

Business • 28 Jul 20

Cathal Friel